Skip to main content
Top
Published in: Inflammation 4/2013

01-08-2013

C-Reactive Protein Measurements as a Marker of the Severity of Chronic Obstructive Pulmonary Disease Exacerbations

Authors: Gulistan Karadeniz, Gulru Polat, Gunes Senol, Melih Buyuksirin

Published in: Inflammation | Issue 4/2013

Login to get access

Abstract

Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease of the lungs. Acute exacerbations of COPD (AE-COPD) are a result of infectious or non-infectious instances. In our study, we aimed to determine whether serum C-reactive protein (CRP) levels are predictive indicators for disease severity and prognosis in hospitalized patients with AE-COPD. A total of 64 patients (36 regular ward and 28 ICU patients) were included in the study. Cases were identified and classified according to the Global Initiative for COPD. The first CRP test levels at acceptance at the ward or intensive care unit were counted in the study. CRP levels of patients in intensive care were significantly higher than those of patients in the regular ward. Mean values of CRP were detected to be 6.28 ± 6.53 mg/dl in the regular ward cases and 16.9 ± 12.03 mg/dl in the ICU patients (p < 0.01). The stage of COPD did not indicate a significant difference in terms of CRP values. Mean CRP values were found to be 16.02 ± 6.95 mg/dl in mortal cases and 9.76 ± 11.09 mg/dl in survivors (p < 0.01). High CRP levels were considered as a prognostic parameter and indicator of severity of AE-COPD. Increased mortality risk was found to be associated with high CRP values.
Literature
2.
go back to reference Wedzicha, J.A., and G.C. Donaldson. 2003. Exacerbations of chronic obstructive pulmonary disease. Respiratory Care 48: 1204–1213.PubMed Wedzicha, J.A., and G.C. Donaldson. 2003. Exacerbations of chronic obstructive pulmonary disease. Respiratory Care 48: 1204–1213.PubMed
3.
go back to reference Reynolds, H.Y. 2004. Chronic obstructive pulmonary disease. In Principles and practice of infectious diseases, 6th ed, ed. G.L. Mandell, J.E. Bennett, and R. Dolin, 706–710. Philadelphia: Churchill Livingstone. Reynolds, H.Y. 2004. Chronic obstructive pulmonary disease. In Principles and practice of infectious diseases, 6th ed, ed. G.L. Mandell, J.E. Bennett, and R. Dolin, 706–710. Philadelphia: Churchill Livingstone.
4.
go back to reference Johannes, M.A.D., S. Marianne, S. Dominic, L.K. Dirk, L. René, and M.J. Henk. 2010. Procalcitonin vs C-reactive protein as predictive markers of response to antibiotic therapy in acute exacerbations of COPD. Chest 138: 1108–1115.CrossRef Johannes, M.A.D., S. Marianne, S. Dominic, L.K. Dirk, L. René, and M.J. Henk. 2010. Procalcitonin vs C-reactive protein as predictive markers of response to antibiotic therapy in acute exacerbations of COPD. Chest 138: 1108–1115.CrossRef
5.
go back to reference Shameem, M., R. Bhargava, and Z. Ahmad. 2011. Association between serum C-reactive protein levels and other important predictive markers of outcome in COPD. Acta Medica Iranica 49: 18–20.PubMed Shameem, M., R. Bhargava, and Z. Ahmad. 2011. Association between serum C-reactive protein levels and other important predictive markers of outcome in COPD. Acta Medica Iranica 49: 18–20.PubMed
6.
go back to reference Tascı, C., A. Balkan, N. Karadurmus, S. Inal, S. Kılıç, and M. Ozkan. 2008. The importance of serum procalcitonin levels in patients with chronic obstructive pulmonary disease exacerbations. Turkish Journal of Medical Sciences 38: 139–145. Tascı, C., A. Balkan, N. Karadurmus, S. Inal, S. Kılıç, and M. Ozkan. 2008. The importance of serum procalcitonin levels in patients with chronic obstructive pulmonary disease exacerbations. Turkish Journal of Medical Sciences 38: 139–145.
7.
go back to reference Garcia-Rio, F., M. Miravitlles, J.B. Soriano, L. Munoz, E.D. Tauleria, and G. Sanchez. 2010. Systemic inflammation in chronic obstructive pulmonary disease: A population-based study. Respiratory Research 11: 63–75.PubMedCrossRef Garcia-Rio, F., M. Miravitlles, J.B. Soriano, L. Munoz, E.D. Tauleria, and G. Sanchez. 2010. Systemic inflammation in chronic obstructive pulmonary disease: A population-based study. Respiratory Research 11: 63–75.PubMedCrossRef
8.
go back to reference Peisajovich, A., L. Marnell, C. Mold, and T.W. Du Clos. 2008. C-reactive protein at the interface between innate immunity and inflammation. Expert Review of Clinical Immunology 4: 379–390.PubMedCrossRef Peisajovich, A., L. Marnell, C. Mold, and T.W. Du Clos. 2008. C-reactive protein at the interface between innate immunity and inflammation. Expert Review of Clinical Immunology 4: 379–390.PubMedCrossRef
9.
go back to reference Dinarello, C.A. 1996. The acute phase response. In Cecil textbook of medicine, 20th ed, ed. J.C. Bennett and F. Plum, 1535–1537. Philadelphia: WB Saunders. Dinarello, C.A. 1996. The acute phase response. In Cecil textbook of medicine, 20th ed, ed. J.C. Bennett and F. Plum, 1535–1537. Philadelphia: WB Saunders.
10.
go back to reference National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically—Sixth edition: Approved standard M7-A6. NCCLS, Wayne. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically—Sixth edition: Approved standard M7-A6. NCCLS, Wayne.
11.
go back to reference Horan, T.C., and R.P. Gaynes. 2004. Surveillance of nosocomial infections. In Hospital epidemiology and infection control, 3rd ed, ed. C.G. Mayhall, 1659–1702. Philadelphia: Lippincott Williams & Wilkins. Horan, T.C., and R.P. Gaynes. 2004. Surveillance of nosocomial infections. In Hospital epidemiology and infection control, 3rd ed, ed. C.G. Mayhall, 1659–1702. Philadelphia: Lippincott Williams & Wilkins.
12.
go back to reference Erturk, E., M. Polatlı, A. Kocabaş, N. Yıldırım, A. Gürgün, S. Saryal, and N. Kokturk. 2010. Consensus report of Turkish Thoracic Society for the diagnosis and treatment of chronic obstructive lung disease. Turkish Thoracic Journal 11(Suppl 1): S5–S63 Erturk, E., M. Polatlı, A. Kocabaş, N. Yıldırım, A. Gürgün, S. Saryal, and N. Kokturk. 2010. Consensus report of Turkish Thoracic Society for the diagnosis and treatment of chronic obstructive lung disease. Turkish Thoracic Journal 11(Suppl 1): S5–S63
13.
go back to reference Lacoma, A., C. Prat, F. Andreo, L. Lores, J. Ruiz-Manzano, V. Ausina, and J. Domínguez. 2011. Value of procalcitonin, C-reactive protein, and neopterin in exacerbations of chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease 6: 157–169. doi:10.2147/COPD.S16070.PubMed Lacoma, A., C. Prat, F. Andreo, L. Lores, J. Ruiz-Manzano, V. Ausina, and J. Domínguez. 2011. Value of procalcitonin, C-reactive protein, and neopterin in exacerbations of chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease 6: 157–169. doi:10.​2147/​COPD.​S16070.PubMed
14.
go back to reference Seppa, Y., A. Bloigu, P.O. Honkanen, L. Miettine, and H. Syrjala. 2001. Severity assessment of lower respiratory tract infection in elderly patients in primary care. Archives of Internal Medicine 161: 2709–2713.PubMedCrossRef Seppa, Y., A. Bloigu, P.O. Honkanen, L. Miettine, and H. Syrjala. 2001. Severity assessment of lower respiratory tract infection in elderly patients in primary care. Archives of Internal Medicine 161: 2709–2713.PubMedCrossRef
15.
go back to reference Almirall, J., I. Bolibar, P. Toran, G. Pera, X. Boquet, X. Balanzó, et al. 2004. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest 125: 1335–1342.PubMedCrossRef Almirall, J., I. Bolibar, P. Toran, G. Pera, X. Boquet, X. Balanzó, et al. 2004. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest 125: 1335–1342.PubMedCrossRef
16.
go back to reference Lacoma, A., C. Prat, F. Andreo, and J. Dominguez. 2009. Biomarkers in the management of COPD. European Respiratory Review 18: 96–104.PubMedCrossRef Lacoma, A., C. Prat, F. Andreo, and J. Dominguez. 2009. Biomarkers in the management of COPD. European Respiratory Review 18: 96–104.PubMedCrossRef
17.
go back to reference Dahl, M., J. Vestbo, P. Lange, S.E. Bojesen, A. Tybjaerg-Hansen, and B.G. Nordestgaard. 2007. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 175: 250–255.PubMedCrossRef Dahl, M., J. Vestbo, P. Lange, S.E. Bojesen, A. Tybjaerg-Hansen, and B.G. Nordestgaard. 2007. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 175: 250–255.PubMedCrossRef
18.
go back to reference Gan, W.Q., S.F.P. Man, A. Senthilselvan, and D.D. Sin. 2004. Association between chronic obstructive pulmonary disease and systemic inflammation: A systematic review and meta-analysis. Thorax 59: 574–580.PubMedCrossRef Gan, W.Q., S.F.P. Man, A. Senthilselvan, and D.D. Sin. 2004. Association between chronic obstructive pulmonary disease and systemic inflammation: A systematic review and meta-analysis. Thorax 59: 574–580.PubMedCrossRef
19.
go back to reference Tofan, F., M.H. Rahimi-Rad, Y. Rasmi, and S. Rahimirad. 2012. High sensitive C-reactive protein for prediction of adverse outcome in acute exacerbation of chronic obstructive pulmonary disease. Pneumologia 61: 160–162.PubMed Tofan, F., M.H. Rahimi-Rad, Y. Rasmi, and S. Rahimirad. 2012. High sensitive C-reactive protein for prediction of adverse outcome in acute exacerbation of chronic obstructive pulmonary disease. Pneumologia 61: 160–162.PubMed
20.
go back to reference Zhang, Y., H. Bunjhoo, W. Xiong, Y. Xu, and D. Yang. 2012. Association between C-reactive protein concentration and chronic obstructive pulmonary disease: A systematic review and meta-analysis. The Journal of International Medical Research 40: 1629–1635.PubMedCrossRef Zhang, Y., H. Bunjhoo, W. Xiong, Y. Xu, and D. Yang. 2012. Association between C-reactive protein concentration and chronic obstructive pulmonary disease: A systematic review and meta-analysis. The Journal of International Medical Research 40: 1629–1635.PubMedCrossRef
21.
go back to reference Mannino, D.M., E.S. Ford, and S.C. Redd. 2003. Obstructive and restrictive lung disease and markers of inflammation: Data from the Third National Health and Nutrition Examination. American Journal of Medicine 114: 758–762.PubMedCrossRef Mannino, D.M., E.S. Ford, and S.C. Redd. 2003. Obstructive and restrictive lung disease and markers of inflammation: Data from the Third National Health and Nutrition Examination. American Journal of Medicine 114: 758–762.PubMedCrossRef
22.
go back to reference Broekhuizen, R., E.F.M. Wouters, E.C. Creutzberg, and A.M.W.J. Schols. 2006. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 61: 17–22.PubMedCrossRef Broekhuizen, R., E.F.M. Wouters, E.C. Creutzberg, and A.M.W.J. Schols. 2006. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 61: 17–22.PubMedCrossRef
23.
go back to reference Stockley, R.A., C. O'Brien, A. Pye, and S.L. Hill. 2000. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 117: 1638–1645.PubMedCrossRef Stockley, R.A., C. O'Brien, A. Pye, and S.L. Hill. 2000. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 117: 1638–1645.PubMedCrossRef
24.
go back to reference Nural, S., E. Gunay, B. Halici, S. Celik, and M. Unlu. 2013. Inflammatory processes and effects of continuous positive airway pressure (CPAP) in overlap syndrome. Inflammation 36: 66–74.PubMedCrossRef Nural, S., E. Gunay, B. Halici, S. Celik, and M. Unlu. 2013. Inflammatory processes and effects of continuous positive airway pressure (CPAP) in overlap syndrome. Inflammation 36: 66–74.PubMedCrossRef
25.
go back to reference Yanbaeva, D.G., M.A. Dentener, E.C. Creutzberg, G. Wesseling, and E.F. Wouters. 2007. Systemic effects of smoking. Chest 131: 1557–1566.PubMedCrossRef Yanbaeva, D.G., M.A. Dentener, E.C. Creutzberg, G. Wesseling, and E.F. Wouters. 2007. Systemic effects of smoking. Chest 131: 1557–1566.PubMedCrossRef
26.
go back to reference Pinto-Plata, V.M., H. Mullerova, J.F. Toso, M. Feudjo-Tepie, J.B. Soriano, and R.S. Vessey. 2006. C-reactive protein in patients with COPD, control smokers and nonsmokers. Thorax 6: 23–28. Pinto-Plata, V.M., H. Mullerova, J.F. Toso, M. Feudjo-Tepie, J.B. Soriano, and R.S. Vessey. 2006. C-reactive protein in patients with COPD, control smokers and nonsmokers. Thorax 6: 23–28.
27.
go back to reference Gan, W.Q., S.F. Paul Man, and D.D. Sin. 2005. The interactions between cigarette smoking and reduced lung function on systemic inflammation. Chest 127: 558–564.PubMedCrossRef Gan, W.Q., S.F. Paul Man, and D.D. Sin. 2005. The interactions between cigarette smoking and reduced lung function on systemic inflammation. Chest 127: 558–564.PubMedCrossRef
28.
go back to reference Lowy, F.D. 1998. Staphylococcus aureus infections. The New England Journal of Medicine 339: 520–532.PubMedCrossRef Lowy, F.D. 1998. Staphylococcus aureus infections. The New England Journal of Medicine 339: 520–532.PubMedCrossRef
29.
go back to reference Kadioglu, A., and P.W. Andrew. 2004. The innate immune response to pneumococcal lung infection: The untold story. Trends in Immunology 25: 143–149.PubMedCrossRef Kadioglu, A., and P.W. Andrew. 2004. The innate immune response to pneumococcal lung infection: The untold story. Trends in Immunology 25: 143–149.PubMedCrossRef
30.
go back to reference Sethi, S., C. Wrona, K. Eschberger, P. Lobbins, X. Cai, and T.F. Murphy. 2008. Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 177: 491–497.PubMedCrossRef Sethi, S., C. Wrona, K. Eschberger, P. Lobbins, X. Cai, and T.F. Murphy. 2008. Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 177: 491–497.PubMedCrossRef
31.
go back to reference Murphy, T.F. 2006. The role of bacteria in airway inflammation in exacerbations of chronic obstructive pulmonary disease. Current Opinion in Infectious Diseases 19: 225–230.PubMedCrossRef Murphy, T.F. 2006. The role of bacteria in airway inflammation in exacerbations of chronic obstructive pulmonary disease. Current Opinion in Infectious Diseases 19: 225–230.PubMedCrossRef
32.
go back to reference Peng, C., C. Tian, Y. Zhang, X. Yang, H. Fan, and Y. Feng. 2013. C-reactive protein levels predict bacterial exacerbation in patients with chronic obstructive pulmonary disease. The American Journal of the Medical Sciences 345: 190–194.PubMedCrossRef Peng, C., C. Tian, Y. Zhang, X. Yang, H. Fan, and Y. Feng. 2013. C-reactive protein levels predict bacterial exacerbation in patients with chronic obstructive pulmonary disease. The American Journal of the Medical Sciences 345: 190–194.PubMedCrossRef
Metadata
Title
C-Reactive Protein Measurements as a Marker of the Severity of Chronic Obstructive Pulmonary Disease Exacerbations
Authors
Gulistan Karadeniz
Gulru Polat
Gunes Senol
Melih Buyuksirin
Publication date
01-08-2013
Publisher
Springer US
Published in
Inflammation / Issue 4/2013
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-013-9625-z

Other articles of this Issue 4/2013

Inflammation 4/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine